目的 探究復(fù)方鮮竹瀝液聯(lián)合異丙托溴銨治療慢性阻塞性肺疾病急性加重期的療效。方法 選取2015年1月-2016年6月天津市濱海新區(qū)大港醫(yī)院呼吸科收治的慢性阻塞性肺疾病急性加重期患者321例，隨機分為對照組（160例）和治療組（161例）。對照組患者給予異丙托溴銨氣霧劑，2撳/次，2次/d。治療組在對照組的治療基礎(chǔ)上口服復(fù)方鮮竹瀝液，20 mL/次，2次/d。兩組患者均連續(xù)治療7 d。觀察兩組的臨床療效，同時比較兩組治療前后肺功能指標(biāo)、血氣分析指標(biāo)、炎癥因子水平的變化情況。結(jié)果 治療后，對照組和治療組的總有效率分別為86.88%、96.89%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者一秒用力呼氣容積（FEV₁）、一秒用力呼氣容積/用力肺活量（FEV₁/FVC）及最大呼氣中期流量（MMEF）、氧分壓（pO₂）均比治療前顯著升高，二氧化碳分壓（pCO₂）顯著降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；治療后，治療組FEV₁、FEV₁/FVC、MMEF、pO₂均顯著高于對照組，pCO₂低于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者腫瘤壞死因子-α（TNF-α）、人白細胞介素6（IL-6）、C反應(yīng)蛋白（CRP）均明顯降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；治療后，治療組TNF-α、IL-6、CRP水平顯著低于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 復(fù)方鮮竹瀝液聯(lián)合異丙托溴銨治療慢性阻塞性肺疾病急性加重期具有顯著的臨床療效，可顯著改善肺功能和血氣分析指標(biāo)，降低炎癥因子水平，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical efficacy of Compound Xianzhuli Liqulid combined with isopropyl bromide in treatment of acute exacerbations of chronic obstructive pulmonary disease. Methods Patients (321 cases) with acute exacerbations of chronic obstructive pulmonary disease in Department of Respiratory of Dagang Hospital of Tianjin Binhai New Area from January 2001 to June 2016 were randomly divided into control (160 cases) and treatment (161 cases) groups. Patients in the control group were administered with Ipratropium Bromide Aerosol, 2 presses/time, twice daily. Patients in the treatment group were po administered with Compound Xianzhuli Liqulid on the basis of the control group, 20 mL//time, twice daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacy was evaluated, and the changes of lung function indexes, blood gas analysis indexes and inflammatory factor levels in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 86.88% and 96.89%, respectively, and there was difference between two groups (P<0.05). After treatment, FEV₁, FEV₁/FVC, MMEF, and pO₂ in two groups significantly increased, but pCO₂ significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, FEV₁, FEV₁/FVC, MMEF, and pO₂ in the treatment group were higher than those in the control group, and there was difference between two groups (P<0.05). After treatment, TNF-α, IL-6, and CRP significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, TNF-α, IL-6, and CRP in the treatment group were lower than those in the control group, and there was difference between two groups (P<0.05). Conclusion Compound Xianzhuli Liqulid combined with isopropyl bromide has a significant effect in treatment of acute exacerbations of chronic obstructive pulmonary disease, and can significantly improve lung function and blood gas analysis indexes, and also can reduce inflammatory factor levels, which has a certain clinical application value.